Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06585202
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
14
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
ATI-2138
Sponsor
Aclaris Therapeutics, Inc.